asenapine maleate |
|
CHEBI:71245 |
|
A racemate consisting of equal amounts of (R,R)- and (S,S)-asenapine maleate. Used for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features. |
|
This entity has been manually annotated by the ChEBI Team.
|
|
|
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
|
|
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
psychotropic drug
A loosely defined grouping of drugs that have effects on psychological function.
second generation antipsychotic
Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements.
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
|
|
View more via ChEBI Ontology
rac-(3aR,12bR)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-2-ium (2Z)-3-prop-2-enoate
|
rac-(3aR,12bR)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-but-2-enedioate
|
(±)-asenapine maleate
|
ChEBI
|
(3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo(2,3:6,7)oxepino(4,5-c)pyrrole (2Z)-2-butenedioate
|
ChemIDplus
|
(3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-2-ium (2Z)-3-prop-2-enoate
|
ChEBI
|
(3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-but-2-enedioate
|
ChEBI
|
trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate
|
ChemIDplus
|
3647286
|
Reaxys Registry Number
|
Reaxys
|
85650-56-2
|
CAS Registry Number
|
KEGG DRUG
|
85650-56-2
|
CAS Registry Number
|
ChemIDplus
|
17440629
|
PubMed citation
|
Europe PMC
|
17609744
|
PubMed citation
|
Europe PMC
|
19088949
|
PubMed citation
|
Europe PMC
|
19229381
|
PubMed citation
|
Europe PMC
|
19876039
|
PubMed citation
|
Europe PMC
|
20135021
|
PubMed citation
|
Europe PMC
|
20216523
|
PubMed citation
|
Europe PMC
|
20232719
|
PubMed citation
|
Europe PMC
|
20448862
|
PubMed citation
|
Europe PMC
|
20950326
|
PubMed citation
|
Europe PMC
|
21274390
|
PubMed citation
|
Europe PMC
|
21323396
|
PubMed citation
|
Europe PMC
|
21446639
|
PubMed citation
|
Europe PMC
|
21651314
|
PubMed citation
|
Europe PMC
|
22778826
|
PubMed citation
|
Europe PMC
|
PMC3368685
|
PubMed Central citation
|
Europe PMC
|
|